Frueh Klaus 4
4 · Vir Biotechnology, Inc. · Filed Oct 18, 2019
Insider Transaction Report
Form 4
Frueh Klaus
Director
Transactions
- Conversion
Common Stock
2019-10-16+218,400→ 362,844 total(indirect: See footnote) - Conversion
Series A-2 Convertible Preferred Stock
2019-10-16−218,400→ 0 total(indirect: See footnote)→ Common Stock (218,400 underlying)
Holdings
- 77,777
Common Stock
Footnotes (2)
- [F1]Each share of the Issuer's Series A-2 Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- [F2]The shares are held in the name of the Klaus and Renate Frueh Revocable Trust Dated June 26, 2017.